Ouro Medicines Announces Expansion of Clinical Development for OM336 in Sjögren's Disease and Idiopathic Inflammatory Myopathy

Multinational basket study extends "immune reset" approach into additional B and plasma cell-mediated indications First Phase 1b study data expected in 2026 SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company developing immune reset...